As of February 19 2026 a new regulatory news item describes a head to head clinical investigation comparing two topical tear substitutes in moderate to severe dry eye disease. The sponsor is FB Vision S.p.A and the trial is listed on ClinicalTrials.gov under NCT07412860. The study compares a tear substitute with an ancillary medicinal substance named FBV_01 against Hyaluronic Acid at 0.3 percent concentration using HYLO-VISION SafeDrop Gel. The objective is to gather data on product performance and safety to inform regulatory and clinical decisions for DED management.
What is being compared in this trial?
In this study the comparator arms are two topical tear substitutes. FBV_01 is described as a tear substitute that includes an ancillary medicinal substance. The control product is Hyaluronic Acid 0.3 percent formulated as HYLO-VISION SafeDrop Gel. Subjects with moderate to severe DED are enrolled to receive one of these devices. The design aligns with regulatory considerations for device and combination product investigations in ocular surface disease.
Who sponsors and what is the regulatory context?
The sponsor is FB Vision S.p.A. The article notes a device oriented investigation and the trial is registered on ClinicalTrials.gov. The MDR Annex XIV context applies for high risk devices and combination products; The article emphasizes that sponsor statements exist in the clinical trial record; The regulatory framing is documentary only since the source_text doesn’t mention results, safety events, or compliance statements.
Who is eligible and what is the trial status?
The source text lists the condition as Dry Eye Syndromes and Dry Eye Disease. The trial recruits participants with moderate to severe DED. The status shows Recruiting. No results are provided in the source. The status may change and more information is available on ClinicalTrials.gov.
What does the intervention entail?
The two devices tested are FBV_01 and HYLO-VISION SafeDrop Gel. The comparison covers topical tear substitutes intended to support tear film and ocular surface. The safety profile and performance endpoints would be defined by the study protocol and regulatory filings. This section underscores the need for consistent labeling and patient information per MDR requirements.
Why does this matter for regulators and clinicians?
Head to head data on tear substitutes can inform product labeling and post market surveillance expectations. If the trial shows comparable performance with safety signals acceptable to regulators, clinicians may have additional options for dry eye treatment in moderate to severe disease. The article notes the sponsor is actively pursuing evidence and the registration remains accessible to the public for independent appraisal.
FAQ
- 1. When was this study registered
The article references a ClinicalTrials.gov record NCT07412860 with sponsor FB Vision S.p.A. The current status is Recruiting. - 2. What devices are compared
FBV_01 tear substitute with ancillary medicinal substance versus HYLO-VISION SafeDrop Gel containing Hyaluronic Acid 0.3%. - 3. Where can I find more information
ClinicalTrials.gov record at https://clinicaltrials.gov/study/NCT07412860?term=medical+device
Conclusion and implications for practitioners
In summary this trial aims to provide head to head comparison data for two tear substitutes in moderate to severe DED. Pending results can influence labeling and clinical decision making. Readers should monitor the ClinicalTrials.gov record for updates.
Disclaimer This article is intended for professionals. It is not legal advice. Regulatory interpretations should be verified with official MDR guidance and sponsor communications.
For full information about the announcement see the link below
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07412860?term=medical+device